Lifitegrast not checked
Lunan Better Pharmaceutical Co., LTD.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- Lymphocyte Function-Associated Antigen-1 Antagonist FDA class
- How it’s given
- “Instill one drop of the eye solution in each eye, twice a day (morning and evening, approximately 12 hours apart), for a treatment period of 12 weeks.”In the company’s words, NCT06879782 on ClinicalTrials.gov
- Tested for
- Dry Eye Disease (DED)
- Main trialPhase 3
- “This study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of Lifitegrast Ophthalmic Solution.”In the company’s words, NCT06879782 on ClinicalTrials.gov
Other drugs for Dry Eye Disease (DED)
- DeucravacitinibBristol Myers Squibb · Phase 3
- LicaminlimabOculis · Phase 2/3
- NipocalimabJanssen Research & Development, LLC · Phase 3
- VVN001VivaVision Biotech, Inc · Phase 3
- CAM-101Cambium Bio Limited · Phase 3
- TelitaciceptVor Biopharma · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 28 Mar 2026 | Phase III Clinical Study of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026